Novavax announced that the Medicines and Healthcare products Regulatory Agency in the United Kingdom has granted full marketing authorization for its prototype COVID-19 vaccine Nuvaxovid for individuals aged 12 and older for active immunization to help prevent COVID-19.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVAX:
- Largest borrow rate increases among liquid names
- Novavax remains ‘confident’ in rollout of updated COVID-19 vaccine in U.S.
- EU delays approval of Novavax’s revised COVID vaccine, FT reports
- Novavax (NASDAQ:NVAX): Europe Delays Vaccine Approval
- Novavax (NASDAQ:NVAX) Vaccine Doses Become Available Across the U.S.